KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Current Liabilities: 2013-2024

Historic Total Current Liabilities for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $35.6 million.

  • Xenon Pharmaceuticals' Total Current Liabilities rose 29.10% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 29.10%. This contributed to the annual value of $35.6 million for FY2024, which is 30.50% up from last year.
  • Xenon Pharmaceuticals' Total Current Liabilities amounted to $35.6 million in FY2024, which was up 30.50% from $27.3 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Total Current Liabilities ranged from a high of $35.6 million in FY2024 and a low of $14.3 million during FY2021.
  • Over the past 3 years, Xenon Pharmaceuticals' median Total Current Liabilities value was $27.3 million (recorded in 2023), while the average stood at $28.5 million.
  • In the last 5 years, Xenon Pharmaceuticals' Total Current Liabilities crashed by 65.93% in 2020 and then soared by 58.51% in 2022.
  • Xenon Pharmaceuticals' Total Current Liabilities (Yearly) stood at $14.8 million in 2020, then dropped by 3.11% to $14.3 million in 2021, then surged by 58.51% to $22.7 million in 2022, then grew by 20.13% to $27.3 million in 2023, then spiked by 30.50% to $35.6 million in 2024.